Subcutaneous alemtuzumab in patients with refractory/relapsed B-CLL after a fludarabine-based regimen.

被引：0
|
作者：
Bezares, R.
Stemmelin, G.
Argentieri, D.
Lanari, E.
Guy-Garay, E.
Campestri, R.
Bartomioli, M.
Garcia, J.
Giralt, S.
Milone, G.
机构：
[1] Hosp Gen Agudos, Buenos Aires, DF, Argentina
[2] Hosp Britan, Buenos Aires, DF, Argentina
[3] Sanatorio Mitre, Buenos Aires, DF, Argentina
[4] Ctr Med Corrientes, Buenos Aires, DF, Argentina
[5] CEMIC, Buenos Aires, DF, Argentina
[6] Hosp Pena Bahia Blanca, Buenos Aires, DF, Argentina
[7] Hosp Privado Cordova, Cordova, Argentina
[8] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] Fundaleu, Buenos Aires, DF, Argentina
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：360S / 360S
页数：1
相关论文
共 50 条
  • [21] High response rates and reduced first-dose reactions with subcutaneous alemtuzumab in patients with relapsed and refractory CLL.
    Ciolli, S
    Gigli, F
    Mannelli, F
    Fanci, R
    Grossi, A
    Longo, G
    Rigacci, L
    Bosi, A
    BLOOD, 2003, 102 (11) : 357B - 358B
  • [22] Management of cytomegalovirus (CMV) reactivation in B-CLL patients receiving sequential treatment with fludarabine (FAMP) including regimens and alemtuzumab.
    Rossi, V
    Montillo, M
    Tedeschi, A
    Cafro, AM
    Morra, E
    BLOOD, 2004, 104 (11) : 691A - 691A
  • [23] Pentostatin and cyclophosphamide: A new active regimen for patients with fludarabine refractory CLL.
    Weiss, MA
    Maslak, PG
    Jurcic, JG
    Scheinberg, DA
    Horgan, DE
    BLOOD, 2001, 98 (11) : 633A - 634A
  • [24] Fludarabine-based salvage therapy for refractory/relapsed acute leukemias: A single center experience
    Abbasi, Abdul Muqtadir
    Shaikh, Usman
    Ali, Natasha
    Haider, Mohammad Nadir
    LEUKEMIA RESEARCH REPORTS, 2021, 15
  • [25] Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL study group
    Elter, T.
    James, R.
    Wendtner, C. M.
    Stilgenbauer, S.
    Winkler, D.
    Ritgen, M.
    Hallek, M.
    Engert, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 194 - 194
  • [26] Combination of fludarabine (FAMP) cyclophosphamide (CTX) and alemtuzumab for patients with relapsed chronic lymphocytic leukemia (CLL).
    Tedeschi, A
    Montillo, M
    Miqueleiz, S
    Draisci, M
    Ricci, F
    Scarpati, B
    Mura, ME
    Crugnola, M
    Morra, E
    BLOOD, 2005, 106 (11) : 341B - 341B
  • [27] Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL Study Group
    Elter, T.
    James, R.
    Wendtner, C. M.
    Stilgenbauer, S.
    Winkler, D.
    Ritgen, M.
    Hallek, M.
    Engert, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Feasibility of alemtuzumab re-treatment in heavily pretreated refractory B-CLL/SLL.
    Thieblemont, C
    Bouafia, F
    Antal, D
    Salles, G
    Coiffier, B
    BLOOD, 2003, 102 (11) : 360B - 360B
  • [29] Different in vitro alemtuzumab induced apoptosis on T and B lymphocytes of B-CLL patients
    Berretta, S.
    Parrinello, N.
    Fargione, G.
    Tibullo, D.
    Stagno, F.
    Chiarenza, A.
    Palumbo, G. A.
    Di Raimondo, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 22 - 23
  • [30] A fludarabine-based conditioning regimen for patients with thalassemia: report of two cases
    Sykora, KW
    Schrauder, A
    Beilken, A
    Welte, K
    BONE MARROW TRANSPLANTATION, 2001, 27 : S193 - S194
12345